Home » Market News » DirectorsTalk Highlights » pre|CISION prodrug technology and AVA6000 clinical trial
Avacta Group Plc

pre|CISION prodrug technology and AVA6000 clinical trial

Alastair Smith provides overview of pre|CISIONTM prodrug technology and update on AVA6000 clinical trial

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.